| Bioactivity | Dutogliptin tartrate (PHX-1149) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus. |
| Target | DPP4 |
| In Vivo | Dutogliptin exhibits low plasma protein binding (11%) and is rapidly absorbed with a Tmax of 3-4 h and a half-life of 10-13 h. Dutogliptin is metabolically stable and does not inhibit or induce the activity of major CYP450s[2]. |
| Name | Dutogliptin tartrate |
| CAS | 890402-81-0 |
| Formula | C14H26BN3O9 |
| Molar Mass | 391.18 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Marier JF, et al. Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. Clin Pharmacol Drug Dev. 2014 Jul;3(4):297-304. [2]. Pattzi HM, et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. |